The pursuit of market outperformance leads investors to the practice of hand-picking stocks. Skillful choices can be a catalyst for significant wealth enhancement.
In the latest session, Sangamo Therapeutics Inc (NASDAQ: SGMO) closed at $0.51 up 5.44% from its previous closing price of $0.49. In other words, the price has increased by $5.44 from its previous closing price. On the day, 1.03 million shares were traded. SGMO stock price reached its highest trading level at $0.5291 during the session, while it also had its lowest trading level at $0.4701.
Ratios:
For a deeper understanding of Sangamo Therapeutics Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.98 and its Current Ratio is at 1.98. In the meantime, Its Debt-to-Equity ratio is 0.46 whereas as Long-Term Debt/Eq ratio is at 0.40.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, RBC Capital Mkts on November 03, 2023, Downgraded its rating to Sector Perform and sets its target price to $2 from $6 previously.
On April 28, 2023, BofA Securities Downgraded its rating to Underperform which previously was Neutral and also lowered its target price recommendation from $5 to $1.50.
Wedbush Upgraded its Neutral to Outperform on February 27, 2023, while the target price for the stock was maintained at $16.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Sep 26 ’23 when BIOGEN INC. sold 6,000,000 shares for $0.50 per share. The transaction valued at 3,000,000 led to the insider holds 17,652,466 shares of the business.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, SGMO now has a Market Capitalization of 104176184 and an Enterprise Value of 48612600. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.59 while its Price-to-Book (P/B) ratio in mrq is 1.10. Its current Enterprise Value per Revenue stands at 0.276 whereas that against EBITDA is -0.556.
Stock Price History:
Over the past 52 weeks, SGMO has reached a high of $1.78, while it has fallen to a 52-week low of $0.29. The 50-Day Moving Average of the stock is -35.90%, while the 200-Day Moving Average is calculated to be -30.47%.
Shares Statistics:
For the past three months, SGMO has traded an average of 2.39M shares per day and 1543110 over the past ten days. A total of 203.67M shares are outstanding, with a floating share count of 183.15M. Insiders hold about 10.07% of the company’s shares, while institutions hold 46.87% stake in the company. Shares short for SGMO as of 1711584000 were 11411843 with a Short Ratio of 4.78, compared to 1709164800 on 10061503. Therefore, it implies a Short% of Shares Outstanding of 11411843 and a Short% of Float of 6.39.
Earnings Estimates
Current recommendations for the stock of the company come from Sangamo Therapeutics, Inc. analysts. The consensus estimate for the next quarter is $71.84, with high estimates of $13.35 and low estimates of $4.01.
